Study Objectives: Distinct clinical phenotypes of obstructive sleep apnea (OSA) have been identified: Disturbed Sleep, Minimally Symptomatic, and Sleepy. Determining whether these phenotypes respond differently to standard treatment helps us to create a foundation for personalized therapies. We compared responses to positive airway pressure (PAP) therapy in these clinical OSA phenotypes.
Introduction
While long recognized, the heterogeneity of obstructive sleep apnea (OSA) clinical presentations has been formally characterized only recently. Our team first applied cluster analysis to identify clinical phenotypes of patients with moderate-tosevere OSA in the Icelandic Sleep Apnea Cohort (ISAC), using self-reported symptoms and relevant comorbidities. 1 Cluster analysis groups individuals together based on the specified variables so that members of each cluster are as similar as possible to others within the cluster, but as different as possible compared with those in other clusters. We identified three distinct clusters, including a Disturbed Sleep group, a Minimally Symptomatic group, and an Excessive Daytime Sleepiness (Sleepy) group. 1 The Disturbed Sleep group had the highest probability of experiencing insomnia-related symptoms, including difficulty falling asleep, waking too early, and waking often during the night. Patients in the Minimally Symptomatic group were markedly less likely to report sleep-related symptoms, and they were much more likely to feel rested upon waking. The Sleepy group had a mean Epworth Sleepiness Scale (ESS) score of nearly 16 and a markedly higher probability of sleepinessrelated symptoms, such as falling asleep involuntarily and dozing off when driving. Understanding how patients with distinct clinical phenotypes and specific underlying symptoms respond to standard treatment for OSA (i.e., positive airway pressure, PAP) creates a foundation for personalized therapies and optimal clinical approaches for management of OSA.
In the current study, we examined symptom changes in the three OSA clinical phenotypes in the ISAC study 2 years after PAP initiation. We hypothesized that specific symptom changes at follow-up would vary depending on baseline cluster assignment. Furthermore, we compared PAP adherence and changes in other clinical outcomes including health status and comorbidities by clinical phenotypes among the clusters and examined how PAP adherence may influence treatment responses among and within the clusters. Some of the results of this study have previously been reported in the form of an abstract. 2 
Methods

Study Sample
This report includes 706 participants with baseline and 2-year follow-up data from the ISAC, a prospective clinical cohort of people with moderate-to-severe OSA (apnea-hypopnea index [AHI] ≥ 15 events per hour) from the entire population of Iceland, described previously in detail. 1, [3] [4] [5] There were no significant differences in gender, age, body mass index (BMI), OSA severity, quality of life, or cluster assignment between included participants (n = 706) and those from the original sample lost to follow-up (n = 79; Supplementary Table S1 ). The Iceland National Bioethics Committee, Data Protection Authority of Iceland, and University of Pennsylvania Institutional Review Board approved the study. Written consent was obtained from all participants.
Study Design
Before starting PAP, each participant completed a type 3 sleep study, physical examination, and questionnaires including the Basic Nordic Sleep Questionnaire (BNSQ), 6 ESS, 7 International
Restless Legs Syndrome Study Group Questionnaire, 8 and 12-Item Short Form Health Survey (SF-12). 9 Self-reported comorbid conditions were validated against medical records. BNSQ is a scale assessing the frequency of subjective sleep complaints in the past 3 months, ranging from 1 (never or less than once per month), 2 (less than once in a week), 3 (once or twice in a week), 4 (three to five times a week), to 5 (every night or almost daily). 6 This instrument is frequently used in epidemiological and genetic research for OSA with demonstrated validity 10 and has been used widely in routine clinical practice in the Nordic countries. 6 Participants were followed for 2 years to allow adequate opportunity to evaluate changes in OSA symptoms. Patients using PAP were assisted by trained staff in optimizing PAP therapy and followed in a continuously updated register. Baseline assessments were repeated and PAP adherence was examined at the follow-up visit.
11
Outcome Variables
In the original cluster analyses, we identified three clinical phenotypes using 23 variables representing clinically significant and prevalent symptoms and comorbidities in the OSA population, mostly drawn from the BNSQ, ESS, SF-12, and the validated medical history. 1 Detailed descriptions of these variables are available in the original report and other reports from the ISAC cohort. 1, 3, 5 We retained these variables for examination as outcomes in the current analyses, including symptom profiles, daytime sleepiness (evaluated by the ESS score), comorbid conditions (existence of hypertension, diabetes, cardiovascular disease, and obstructive lung disease), health status (SF-12), and blood pressure (BP). Symptom profiles were primarily derived from the responses to the questions on the BNSQ. To comprehensively evaluate symptom responses to PAP treatment and avoid focusing exclusively on a few hallmark symptoms of OSA, we examined changes in the individual symptoms that were used to define the symptom clusters at baseline. To highlight responses in symptom-related measures, similar symptoms were grouped together to create symptom "domains," including sleepiness and fatigue-related symptoms, insomniarelated symptoms, apneic symptoms, and other sleep-related complaints.
PAP Adherence
PAP adherence was assessed using both questionnaire and memory card data, as described previously. To compare changes in variables among clusters, we used linear (continuous variables) or logistic (binary variables) mixed models and assessed the significance of the time by cluster interaction term among all participants. Significance of this interaction term was based on an F-statistic with two numerator degrees of freedom and denominator degrees of freedom estimated using the containment method in SAS PROC GLIMMIX. A significant interaction term in the mixed model indicates a difference in the 2-year change in the symptom variable among clusters. Primary analyses examined symptom frequency change using the five-level response variable via linear mixed models; change scores were generally normally distributed around zero, allowing for parametric analysis.
In secondary analyses, we categorized each symptom as "present" if it occurred at least once or twice weekly, as in the original study, 1 and examined change in the likelihood of individual symptoms being present using logistic mixed models; detailed results are presented in Supplemental Material. For these binary outcomes, an a priori rule requiring an adequate number of changes in symptom status (e.g., variability in responses) within a cluster was applied prior to conducting statistical models to prevent model instability and lack of convergence. Specifically, in order to fit the logistic mixed model, we required more than five changes in the symptom presence or absence from baseline to follow-up overall, including at least one change from presence to absence and one change from absence to presence; if a cluster did not meet these criteria, results for that group are presented as N/A. When comparisons among the clusters achieved statistical significance after correction for multiple comparisons (see below), we performed between cluster contrasts to determine which clusters were driving the overall results. To provide more clinically meaningful effect estimates, results of these comparisons are presented as standardized mean differences in change scores for continuous measures (equivalent to Cohen's D) or ratios of within-group odds ratios, along with corresponding 95% confidence intervals. Standardized mean differences were obtained by dividing the observed difference on the original scale by the total phenotypic standard deviation estimated from the mixed model. Based on prior publications on effects for biological sciences, 16 the magnitude of these standardized effect sizes can be interpreted as small (~0.20), medium (~0.50), or large (~0.80), thus providing more clinically relevant interpretations. Within-group estimates are presented on the observed scales, wherever relevant, to help inform clinical expectations in response. Ratio measures such as the within-group odds ratio provide a relative interpretation of the proportional differences in effects between clusters. Analyses comparing clusters were adjusted for primary confounders of gender and baseline age, BMI, and AHI. Moreover, to examine whether the level of PAP adherence mediated the relationship between clinical phenotype and treatment responses, we examined changes in association between clusters and changes in outcome variables after further controlling for PAP adherence group ("full," "partial," or nonuser).
Next, we evaluated the effect of PAP both within and among clusters. Analyses were restricted to adherent ("full") and nonusers, to obtain more robust estimates of PAP effects. First, to test whether there were differences in the PAP effect among OSA clusters, we examined the significance of a three-way interaction term between time, cluster, and PAP adherence group in mixed models similar to those described above. A significant three-way interaction suggests that the effect of PAP adherence on changes in symptoms differs among the three clusters. In addition to this overall evaluation, within each cluster, we examined relationships between changes in symptoms and PAP adherence using similar techniques to those described above. Clinically interpretable effect estimates comparing full users and nonusers within clusters were derived in a similar fashion to between-cluster effects.
To reduce bias and improve causal interpretations of PAP effects, models comparing full users and nonusers were adjusted using a propensity score derived from baseline age, gender, BMI and AHI main effects, squares, and interaction terms. 17 To account for other sources of potential bias in PAP effect estimates, we performed three sensitivity analyses: (1) excluding nonusers who reported alternative OSA treatments (e.g., oral appliance); (2) excluding any patient with >5% weight loss at follow-up; and (3) excluding individuals who reported using PAP but whose PAP devices lacked downloadable memory cards to verify adherence objectively. We utilized the Hochberg step-up method to control α at 5% given multiple comparisons when comparing symptoms among clusters and within a given OSA cluster. 18, 19 Statistically significant p-values after Hochberg correction are shown in bold or specifically noted in results' tables. For comparisons of change scores among clusters, pairwise comparisons were only performed if overall tests were significant after Hochberg correction. In addition, when performing pairwise comparisons among clusters, statistical significance was based on a Bonferronicorrected p < .0167 (given three pairwise comparisons). All analyses were conducted using STATA, Version 14 (StataCorp LP, College Station, TX) or SAS Version 9.4 (SAS Institute, Cary, NC).
Results
Characteristics of the Study Cohort
The majority of study participants were obese, middle-aged men with severe OSA (Table 1 ). There were no baseline differences in gender, BMI, or OSA severity among groups. The Minimally Symptomatic group was slightly older and reported better physical and mental health than the other groups.
Symptoms at Baseline and Follow-up in Each Group
We examined how symptom profiles changed within each group while controlling for gender and baseline age, BMI, and AHI ( Figure 1 ; Table 2 and Supplementary Tables S2 and S3 ). In general, each group exhibited improvement in those symptoms representative of their baseline symptom profile. Greater improvements were observed in the Disturbed Sleep and Sleepy groups, which were more symptomatic at baseline than the Minimally Symptomatic group.
At baseline, the Disturbed Sleep group was characterized by individuals with insomnia-related symptoms, such as difficulty falling asleep (43.2%), waking often at night (90.8%), restless sleep (74.2%), and waking up early (62.3%) (Supplementary Table S2 ). At followup, improvements in the frequency of insomnia-related symptoms such as difficulty falling asleep and restless sleep ranged from 0.28 to 1.25 points on the frequency scale ( Table 2 Tables  S2 and S3 ). When comparing changes in these insomnia-related symptoms between clusters, we observed moderate-to-large effects between the Disturbed Sleep and Minimally Symptomatic patients, with standardized differences ranging from 0.46 to 0.81 in absolute values ( Table 2 ). On the other hand, effects were either small to moderate (~0.35) or nonsignificant when comparing Disturbed Sleep with Sleepy patients. For changes in physical fatigue (Table 2) Members of the Minimally Symptomatic group reported the presence of symptoms at lower rates than other groups prior to starting PAP, despite similar AHI, and they remained relatively asymptomatic at follow-up ( Figure 1 ; Supplementary Table  S2) . Nevertheless, the proportion of patients in the Minimally Symptomatic group reporting daytime sleepiness fell 23.6% (Supplementary Table S2 ). Self-reported frequency of sleepiness and fatigue-related symptoms (e.g., feeling rested on waking, daytime sleepiness, and being physically tired during the day) all showed statistically significant changes (Table 2) ; these within-group effects correspond to generally moderate effects after standardization. A small decrease in ESS (−1.33 points [−2.00, −0.66]) was statistically significant but likely clinically insignificant. Thus, among Minimally Symptomatic patients, effect sizes were comparable to analogous changes in the Disturbed Sleep group only for changes in sleepinessrelated symptoms and were otherwise modest in comparison to symptom changes reported by the Disturbed Sleep and Sleepy groups.
Patients in the Sleepy group reported the highest baseline ESS scores (16.0 ± 3.4); at follow-up, ESS fell five points (mean [95% CI] change = −5.3 [−5.8, −4.8]), much more than in the other groups. Significant reductions were observed in all other symptoms at follow-up except for difficulty falling asleep and waking up too early (Table 2) . Importantly, the Sleepy group acknowledged markedly higher rates of drowsy driving (37.8%) than the other groups at baseline, and the proportion of patients with this symptom fell dramatically at follow-up to 8.1% (Supplementary  Tables S2 and S3 , adjusted OR = 0.06 [0.03, 0.14]). Although the statistical significance of symptoms demonstrating improvement largely overlapped across the Sleepy and Disturbed Sleep groups, moderate-to-large differences based on standardized effect sizes were generally observed for symptom changes in the Sleepy group compared with the Disturbed Sleep group, consistent with changes of larger magnitude among Sleepy patients (Table 2) . Similarly, moderate-to-large effect sizes for differences in symptom change between the Sleepy and the Minimally Symptomatic groups were noted for most sleepiness and sleep quality symptoms.
Comparisons of PAP Adherence Among Groups
In general, patients in the Sleepy group were more likely to be PAP users compared with the Disturbed Sleep and Minimally Symptomatic groups (Table 3 ; 70.0% vs. 61.1% and 60.0%, p = .034). Mean hours per night and number of nights of PAP use over the last 28 days, however, were similar for full users and partial PAP users across all three groups.
Impact of PAP Adherence on Symptom Changes Within Groups
Although full PAP users were more obese and had more severe OSA than nonusers, there were no significant differences between them in age and gender (Supplementary Table S4 ). Overall, we observed statistically significant differences in the PAP effect across clusters for ESS (p < .0001), falling asleep involuntarily (p < .0001), drowsy driving (p = .0017), and feeling rested when waking up (p = .0017) based on three-way interaction tests (Table 4 ). For each of the sleepiness measurements, this difference was driven by large effects related to full PAP usage among the Sleepy patients, compared with Within each cluster, we also compared the magnitude of changes in symptoms between full users and non-PAP users, adjusting for gender and baseline age, BMI, and AHI using a derived propensity score to robustly control for any covariate imbalance ( Table 4) . As expected, full users generally demonstrated larger changes in specific symptom frequency compared with non-PAP users ( Figure 2 ; Table 4 ). Reflecting the established efficacy of PAP for typical OSA symptoms, users in the Sleepy group, which represents the classical clinical presentation of OSA, demonstrated a wider range of clinically and statistically significant PAP effects than either the Disturbed Sleep group or the Minimally Symptomatic group.
In the Disturbed Sleep group, although significant improvements within both full PAP and non-PAP users were noted at follow-up for a number of symptoms (Supplementary Table S5) , moderately large differences in changes (effect sizes between 0.42 and 0.76) were observed when comparing full users and nonusers for sleep quality and insomnia-related symptoms, particularly feeling rested when waking, having restless sleep, waking frequently, and daytime sleepiness. Effect sizes between PAP users and nonusers for other insomnia-related symptoms, such as frequency of difficulty falling asleep and early awakening, were not significant.
In the Minimally Symptomatic group, moderate-to-large effects were observed for falling asleep when relaxed, feeling physically tired, and for witnessed apneas when comparing improvements in full PAP users with nonusers. Smaller effect sizes among full users were noted for sleep quality and sleepiness symptoms compared with nonusers (Table 4) .
Within the Sleepy group, full PAP users reported much greater improvement in numerous symptoms compared with nonusers, with large effect sizes noted for characteristic OSA symptoms including falling asleep involuntarily, drowsy driving, and daytime sleepiness. Improvement in ESS scores was four points larger in full PAP users compared with nonusers (−7.0 vs. −3.0, p < .0001). Moderate differences in the improvement in other symptoms, including waking up with headache and perspiring heavily at night, were also observed.
Within each of the three groups, results were similar in secondary analyses comparing the presence of symptoms in PAP users and nonusers (Supplementary Table S6 ). In sensitivity analyses, we compared full users and non-PAP users after excluding 45 nonusers who reported alternative OSA treatments (Supplementary Table S7 ), excluding 55 full users and non-PAP users with >5% weight loss at follow-up (Supplementary Table  S8) , and removing 79 full PAP users who did not have available objective usage data to confirm their adherence level (Supplementary Table S9 ). Results from each of these sensitivity analyses were similar to analyses including all participants, suggesting that alternative treatments or potential misclassification did not bias overall associations. Analyses to examine the association between cluster membership and change in outcome while controlling for PAP adherence group demonstrated little or no change in associations, indicating that observed associations between cluster and outcome were not mediated or explained by differential adherence to PAP. Between-cluster comparisons performed if overall P-value among clusters was statistically significant after Hochberg correction and results are presented as between-group standardized mean differences in change scores or ratios of within-groups odds ratios (RORs) for symptom development at follow-up. Table  S10 ). BMI increased significantly from baseline to 2-year followup in all groups; the magnitude of change was similar across groups (Table 5) . Similar to previous studies, 20-22 modest effect sizes for increased BMI were observed among full PAP users in the Disturbed Sleep and Sleepy groups (Supplementary Table  S10 ) compared with nonusers. We observed significant differences between clinical subgroups in the proportion of patients reporting hypertension and cardiovascular disease at follow-up (Supplementary Table  S2 ). The Minimally Symptomatic group had higher rates of hypertension (55.0% vs. 46.7% and 41.6%; p = .020) and cardiovascular disease (24.1% vs. 13.5% and 13.4%; p = .002) than the Disturbed Sleep and Sleepy groups. At baseline, comparisons of these major comorbidities had been suggestive, but not statistically different. In adjusted models, the changes in likelihood of incident hypertension or cardiovascular disease were not significantly different among groups (Table 5 ). Changes in reported comorbidities over the 2-year follow-up were insufficiently frequent to obtain robust estimates of PAP effects within groups.
Discussion
Consistent with our hypotheses, the results of this study demonstrate that although symptoms improved overall among each of the three clinical phenotypes of moderate-to-severe OSA, patterns of treatment response after 2 years of PAP therapy varied based on initial clinical presentation. Participants in the Sleepy group experienced broad improvement in daytime and nocturnal OSA symptoms, particularly those related to daytime fatigue and falling asleep involuntarily (including drowsy driving). Physical health was lowest at baseline in this group and improved significantly more in the Sleepy group compared with the others. In contrast, prior analyses in the ISAC cohort using the ESS alone to categorize sleepy patients did not identify patients likely to report a greater improvement in quality of life. 12 Overall, effect sizes were moderate to large when comparing sleepiness, sleep quality, and apneic symptom changes in the Sleepy group to changes in other two groups, especially those in the Minimally Symptomatic group. PAP adherence was most clearly associated with symptom responses in the Sleepy group, within which PAP effect sizes for symptom improvement in adherent patients were generally moderate or large compared with nonusers. In contrast, Minimally Symptomatic patients initially had fewer complaints and thus, unsurprisingly, reported fewer improvements in symptoms. Membership in the Minimally Symptomatic group was associated with a small drop in diastolic BP at follow-up, a finding of potential clinical significance across a larger population of such patients. Daytime sleepiness and physical fatigue also improved significantly at follow-up in this group.
Finally, the Disturbed Sleep group reported significant improvements in a number of symptoms, including those related to insomnia (e.g., difficulty falling asleep and waking often during the night). However, PAP users and nonusers generally reported similar changes in insomnia symptoms, suggesting that factors aside from PAP treatment play important roles in the evolution of insomnia complaints. Other analyses of the relationship between OSA and insomnia in the ISAC cohort have demonstrated that difficulty maintaining sleep responds to PAP therapy while difficulty initiating sleep is not responsive to PAP. 23 Our findings are derived from a large cohort representative of the spectrum of people with moderate-severe OSA across Iceland, with high initial participation (>90%) and retention (>85%) rates. Importantly, they suggest that identifying patients by their clinical phenotypes provides a new paradigm for informing treatment expectations among both providers and patients with OSA. Furthermore, they demonstrate that limiting definitions of treatment response to one or a few indicators, such as change in ESS, may fail to fully capture the benefits of PAP therapy in some subgroups. For instance, members of the Sleepy group reported both an elevated baseline ESS and daytime sleepiness or drowsiness; both complaints improved with treatment. In contrast, despite normal mean ESS scores in the Disturbed Sleep and Minimally Symptomatic groups at baseline, more than two-thirds of patients in both groups acknowledged daytime sleepiness or drowsiness. With treatment, the absolute proportion describing this symptom fell more than 15% in each group. These different patterns support the idea of sleepiness as a multidimensional construct 24 and invite caution when considering how to measure treatment response, especially since .368
Models adjusted for gender, baseline age, BMI, and AHI-derived propensity score. To ensure reliable estimates of group-specific odds ratios with binary outcomes, we required >5 changes in the symptom overall in order to fit a logistic mixed model, as well as ≥1 change from presence to absence and ≥1 change from absence to presence over the follow-up period; if a given group did not meet these criteria, results for that model are presented as "N/A." p-Values shown in bold are statistically significant after Hochberg correction.
*p-Value testing for a three-way interaction among cluster, time, and PAP adherence within the linear mixed model, which tests whether differences in symptom response between full users and nonusers differ among clusters. **p-Value comparing full users vs. nonusers within each cluster.
a Estimates presented as standardized mean difference in change scores (for continuous variables) or ratio of odds ratios (for categorical variables) and associated 95% confidence interval comparing full users vs. nonusers. CI = confidence interval; RLS = restless leg syndrome.
fewer than half of patients in this sample fit the "traditional" Sleepy OSA phenotype. Our approach and results contrast with a recent report describing five clinical and demographic-based phenotypes of OSA, in which effects of OSA therapy were examined using a uniform definition of treatment response (defined as daily CPAP use ≥4 hr and either a decrease in ESS of ≥4 points if ESS > 10 at baseline or an increase in SF-36 energy or vitality of at least seven points) across groups. 25 Groups characterized by milder symptoms with or without comorbid disease (similar to our Disturbed Sleep and Minimally Symptomatic groups) were less likely to achieve successful CPAP treatment response compared with more symptomatic groups. We propose that, alternatively, such patients may not be less likely to respond, but rather, that the nature and magnitude of their treatment success differs from patients with "traditional" OSA characteristics. Among other recent studies in which investigators have used demographic, clinical, and sleep study characteristics to perform cluster analyses in a range of people with OSA, none have assessed response to treatment by initial cluster assignment. [26] [27] [28] [29] Adherence to PAP was significantly higher among patients in the Sleepy group compared with those in the Disturbed Sleep and Minimally Symptomatic groups. A similar finding was reported by a group of European investigators examining PAP adherence in people with OSA defined a priori by clinical phenotype into groups analogous to ours. 29 Nevertheless, we find it notable that rates of CPAP adherence in the Disturbed Sleep and Minimally Symptomatic groups were greater than 60% at 2-year follow-up. Although evidence suggests that greater daytime sleepiness predicts better PAP adherence, 30 patients' perceived benefit from PAP-including improvement in functional status-also predicts continued use. [31] [32] [33] Recognizing that patients with atypical OSA symptoms or normal ESS scores can derive meaningful benefit from PAP treatment helps explain why Minimally Symptomatic and Disturbed Sleep patients remained motivated to use PAP at rates approaching those among traditionally "Sleepy" patients. Consistent with these relatively high adherence rates within each group, our analyses did not support that differential amounts of PAP adherence played a role in different treatment response among three clinical phenotypes. We were initially surprised that across all subgroups, even non-PAP users reported improvements in symptoms, albeit generally modest ones compared with full PAP users. Numerous studies have reported small reductions in OSA symptoms with PAP placebo therapies. [34] [35] [36] [37] Fewer reports have described whether OSA symptoms stabilize, worsen, or improve in untreated individuals. Two studies examining PAP use in moderate and severe OSA observed small symptom improvements after 3 months even among patients with mean use of ≤2 hr per night, including 10%-20% of participants in each study with no nightly PAP use. 38, 39 These findings suggest that, as we observed, untreated patients are likely to report fewer symptoms at follow-up, perhaps due in part to regression to the mean, i.e., the tendency of an extreme observation to be less extreme when re-evaluated. Another possibility is that some participants benefited from alternative treatments (e.g., weight loss and oral appliance); however, we observed similar results after excluding these individuals in sensitivity analyses. Individuals in the ISAC cohort with initial and late insomnia have previously been observed to be less likely to use PAP. 11 In the current analyses, we observed that full PAP users in the Disturbed Sleep group reported moderately greater improvements compared with nonusers in symptoms likely directly related to sleepdisordered breathing, e.g., restless sleep, feeling rested upon waking, daytime sleepiness, and witnessed apneas. However, insomnia-related symptoms such as difficulty falling asleep and To ensure reliable estimates of group-specific odds ratios with binary outcomes, we required >5 changes in the symptom overall in order to fit a logistic mixed model, as well as ≥1 change from presence to absence and ≥1 change from absence to presence over the follow-up period; if a given cluster did not meet these criteria, results for that model are presented as "N/A." If this occurred only within one of the three clusters, we present estimates and pairwise comparisons between the two remaining clusters. *P-value comparing change scores or odds ratios among clusters, with P-values in bold statistically significant after Hochberg correction between clusters.
a Estimate presented as mean change (for continuous measures) or odds ratio (for binary measures) and 95% confidence interval.
b Between-cluster comparisons performed if overall p-value among clusters was statistically significant after Hochberg correction and results are presented as between-group standardized mean differences in change scores or ratios of within groups odds ratios (RORs) for symptom development at follow-up. waking up early appeared relatively resistant to PAP, as changes did not differ significantly between full PAP users and nonusers. In our study, small reductions in diastolic BP 2 years after treatment initiation were limited to the Minimally Symptomatic and Sleepy groups. This is an intriguing finding that needs to be replicated in a larger cohort with the ability to estimate PAP effects, but may have important implications for patient care, especially as a recent study examining rates of cardiovascular comorbidity among patients with similarly defined clinical OSA phenotypes observed that the excessively somnolent group had the lowest comorbidity rate and the insomnia group had the highest. 29 We also found higher proportions of hypertension and cardiovascular disease in the Minimally Symptomatic group at follow-up compared with the Sleepy and Disturbed Sleep groups; however, these changes in comorbidities over the follow-up period were not significantly different. We believe that our results are a necessary first step towards the development of personalized therapies for OSA. Our finding that each of the clinical phenotypes derives benefit suggests that patients in all groups should be considered for OSA treatment and for testing of new clinical options. Our analyses identified the various ways in which patients with specific clinical phenotypes respond to standard therapy, which can help inform the clinical expectations of both patients and providers. For example, clinicians may be more careful to caution people with OSA with insomnia symptoms-i.e., those similar to the Disturbed Sleep phenotype-that these symptoms may not improve with PAP therapy. Meanwhile, providers can suggest more confidently to Minimally Symptomatic patients with moderate-to-severe OSA that they, too, can expect to see moderate improvement in certain OSA symptoms with PAP treatment. Our findings also identify resistant symptoms and other characteristics that can be constructively targeted in future studies.
We anticipate two types of approaches in future investigations-studies that compare the relative efficacy of two or more approaches within a specific clinical phenotype and studies that examine whether a single OSA treatment is more effective for one clinical phenotype than another. For example, whether people with OSA with the Disturbed Sleep phenotype may benefit from targeted therapy for insomnia-related symptoms (e.g., cognitive behavioral therapy for insomnia) should be evaluated in future phenotype-specific trials. Other studies could examine whether treatments such as oral appliances or hypoglossal nerve stimulation are more effective for patients with specific clinical phenotypes or whether different clinical phenotypes vary in their susceptibility to cardiovascular disease and the degree to which antihypertensive effect or cardiovascular risk reduction can be achieved with PAP or other therapies. This latter point is especially important given evidence from the recent SAVE trial that CPAP use may not reduce cardiovascular events in nonsleepy individuals with OSA. 40 Additionally, given the modest improvement in global physical health reported by the Sleepy group, but not the other clinical phenotypes, future studies could examine quality of life differences among OSA phenotypes in greater depth, as group membership may predict improvement in more general measures. Strengths of this study included its large sample size, longterm follow-up, high participation and retention rate, and use of validated instruments and study procedures. All people with OSA in Iceland are referred to a single location for treatment, and in this large prospective observational study, all patients followed the same treatment protocol; neither participants nor study staff was aware of individuals' cluster assignments. Although participants were cognizant of their own PAP use, and thus treatment effects may have been exaggerated among adherent PAP users, the need for observational studies was endorsed recently by the National Institutes of Health. 41 In this context, the use of propensity score adjustment in the examination of PAP treatment effects is an important strength as it reduces biases inherent in observational studies and allows for more robust estimates of treatment effects. Although propensity score methods can adjust for imbalance in measured covariates, we note that unmeasured confounders are controlled for only to the extent that they are correlated with the variables included in the model. Overall, our results highlight the heterogeneity of both OSA clinical presentation and response to PAP treatment. Our study has limitations. As the ISAC cohort included only patients with moderate-severe OSA from Iceland, results may not be applicable to individuals with mild OSA and/or those from other world populations. There were relatively few female participants and adults >65 years of age, reflecting the population of people with OSA in Iceland. Objective PAP adherence data were available for most (76%), but not all participants who used PAP. Standardized self-estimates of PAP use were, however, validated against objective data, 11 and overestimates of PAP usage should bias results towards the null. Furthermore, secondary analyses performed after excluding participants without objective PAP adherence data showed similar results. Although PAP adherence may have been overestimated by our use of data from 28 days prior to follow-up assessment, PAP usage has generally been observed to be stable over time. 42, 43 For non-PAP users, a financial disincentive against keeping the device also existed, as patients in Iceland pay a monthly fee for this equipment. Although we are confident in how PAP adherence was estimated, the lack of objective PAP data for all individuals prevented our inclusion of residual AHI, a measure of PAP efficacy, as a covariate in our analyses. Among individuals prescribed an oral appliance, information on usage of the appliance was unavailable. However, utilization of alternative treatments by PAP nonusers should also bias results towards the null (i.e., no effect of PAP), and sensitivity analyses excluding nonusers reporting alternate treatments produced similar results to those in the full sample. As the groups are based on self-reported symptoms, we note that although symptoms are important in defining a patient's perception of disease and developing clinical treatments, patients can also misclassify or misreport their symptoms. Finally, changes in medications may have affected changes in patient symptoms over the follow-up period.
Conclusions
Different clinical phenotypes of OSA respond differently to PAP treatment, varying by initial OSA presentation. Although we plan to evaluate the generalizability of our results in other, more diverse populations, the results of our study can be applied directly to both current clinical practice and future research. In practice, recommending against treatment for people with OSA who do not initially present with elevated Epworth scores or who articulate insomnia symptoms fails to recognize that such individuals may derive meaningful benefits from treatment of OSA. Assessing a limited spectrum of treatment response measures (e.g., Epworth score) within all people with OSA is likely to underestimate treatment effects, as this benefit varies between subgroups. Our findings underscore the need to consider initial OSA phenotype when designing future trials, perhaps by prospectively defining outcomes specific to different clinical subtypes, or by conducting clinical trials within individuals with specific OSA phenotypes.
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